Join us for the Year in Review Live Webinar | Targeted Therapy for Non-Small Cell Lung Cancer Edition on May 8, 4:30-6pm ET. Dr. Justin Gainor and I will discuss the latest updates with Dr. Neil Love to improve patient care and outcomes. #LCSM

m.researchtopractice.com/Webinars/YiR24…

#AACR24 Neil Bhowmick and Manish Thiruvalluvan present exciting work on persister cells in EGFR NSCLC Cancer at Cedars-Sinai

👏 Attn: We have a new AACR President Patricia M. LoRusso - clinician scientist extraordinaire, Dr. PatLoRusso! Dr. LoRusso outlined some of her priorities today;
🎯 ⬆️ outreach to patients
🎯 ⬆️ recruitment/retention of underrepresented researchers
🎯 @AACR Center for Cancer Clinical Trials
#AACR24

Thank you Conquer Cancer, the ASCO Foundation

#ASCO2023 Cancer at Cedars-Sinai Cedars-Sinai Academic Medicine

Improved PFS with talazoparib and atezolizumab maintenance for SFLN11 selected SCLC patients on S1929 #ASCO23 #LCSM

Enjoy hearing about progress in lung cancer research and treatment at #TTLC23 . It does take a village. Roy Herbst #LCSM

The Lung-MAP trial has new leadership! Hossein Borghaei, DO of Fox Chase Cancer Center & ECOG-ACRIN Cancer Research Group is new chair of the Lung-MAP master protocol. Karen Reckamp, MD, MS of Cedars-Sinai & SWOG Cancer Research Network is vice chair. Roy Herbst & Jyoti D Patel are outgoing chair & vice chair NCI CTEP Clinical Research Friends of Cancer Research Foundation for the National Institutes of Health

Congratulations to the Lung-MAP team for 10 years of dedication and success. Teamwork and commitment to patients is the key. Excellent talk by Roy Herbst at SWOG. It takes a village. David Gandara Jyoti D Patel Mary Redman, Vali Papadimitrakopoulou and so many others. #SWOG #LCSM

Dr. Karen Reckamp Karen Reckamp, MD, MS, Dr. Amin Mirhadi Amin Mirhadi & Dr. Imai Taryne will chair the Curio Science interactive workshop “Opinions in Non-Targetable Early Stage #NSCLC ” on 6/14 at 6-8pm PT. Please register via: [email protected]. Cedars-Sinai #CedarsSinaiCancer

It’s been refreshing to see colleagues and discuss the data at #ASCO2022 We are excited to see coverage #ASCODailyNews of the OS benefit for previously treated NSCLC with ramucirumab and pembrolizumab in S1800A ASCO dailynews.ascopubs.org/do/10.1200/ADN…

#ASCO22

Pleased to present the EGFR-mt subgrp analysis of PACIFIC in which we see no diffs in PFS/OS with durva v PBO, &no concerning safety signals

You know you’ve made it when ⁦David Johnson⁩ comes to your poster ⭐️

⁦⁦Beaumont RCSI Cancer Centre⁩ ⁦Johns Hopkins Thoracic Oncology⁩

NRG1 fusions are part of the NSCLC drivers family!! Zenocutuzumab, a HER2-HER3 bispecific antibody, has significant activity in a NRG1+ tumor agnostic population (n=83), ~50% being NSCLC. ORR=34% overall and 35% in NSCLC. Median DoR 9.1 mo and favorable safety profile. #ASCO22

#CedarsSinaiCancer at #ASCO22 . Dr. Karen Reckamp Karen Reckamp, MD, MS is co-author on the poster “A phase 1/2 study of BLU-945 in patients with common activating EGFR-mutant non–small cell lung cancer: SYMPHONY trial in progress.”ASCO Cedars-Sinai Academic Medicine @CSCancerCare #NSCLC

Looking for a great Metworking opportunity?
Come to our posters on METex14 w excellent lead authors Jennifer Marks, MD and #ASCO22 Merit awardee So Yeon Kim !

(Crediting Stephen V Liu, MD for his great leadership on our Caris POA + coining the new and now licensed term: #Metwork )

#CedarsSinaiCancer at #ASCO22 . Dr. Karen Reckamp Karen Reckamp, MD, MS is co-author on “Characterization of MET exon 14 skipping alterations in non–small cell lung cancer using whole transcriptome sequencing.”ASCO Cedars-Sinai Academic Medicine @CSCancerCare #NSCLC

📣 #ASCO22 simultaneous pub: Lung-MAP study finds ramucirumab ➕ pembro improved OS in pts w #NSCLC previously treated w/ immune ✔️point inhibitors & chemo. fal.cn/3pavG Karen Reckamp, MD, MS Roy Herbst #lcsm

Congrats ⁦Roy Herbst⁩ on being a Giant in Cancer Care! Live from Chicago ⁦OncLive.com⁩

Ready to present. Excited about the data in the oral metastatic lung cancer session.

I’ll be at #ASCO22 presenting the latest treatment options for common + less common targetable #biomarkers for advanced #NSCLC : #EGFR , KRAS, and #HER2 alongside Todd M. Bauer @NarjustDumaMD Karen Reckamp, MD, MS. Join us Sat June 4 in Chicago #lungcancer tinyurl.com/4p8bnt56